What ibogaine is
Ibogaine is a naturally occurring alkaloid found in the root bark of Tabernanthe iboga, a shrub native to Central and West Africa. The plant has a long history of ceremonial use in the Bwiti spiritual tradition. In the body, ibogaine is metabolized into noribogaine, which remains in the system longer than ibogaine itself and is part of ongoing research.
Legal status
In the United States, ibogaine is a Schedule I controlled substance and is not approved by the FDA for any use. It cannot legally be provided as treatment in the U.S. outside of approved research.
In Mexico, ibogaine is not federally controlled, but it has not been formally approved as a medicine and is not uniformly regulated. As a result, standards, staffing, and safety practices vary considerably from one facility to another — which is exactly why careful comparison matters.
What research exists
Much of the published research consists of observational studies, case series, and open-label trials rather than large randomized controlled trials. Researchers continue to study both the safety and the potential effects of ibogaine and related compounds. The existing evidence does not establish that ibogaine treats or cures any condition, and findings should be interpreted cautiously.
Known risks
Published literature describes serious risks, including:
- QT-interval prolongation — a change in the heart's electrical cycle
- Life-threatening heart-rhythm disturbances (arrhythmias)
- Deaths reported in the literature, often involving pre-existing heart conditions or interactions with other substances or medications
- Neurologic effects such as ataxia (loss of coordination) during and after the acute phase
- Interactions with many medications and substances
- An intense acute phase that commonly lasts 24 hours or more
Groups identified as higher-risk in published research
- People with significant heart, liver, or kidney conditions
- People taking medications that affect heart rhythm
- People who are pregnant
- People with a history of psychosis or other serious psychiatric conditions
This list is informational and not exhaustive. Only a facility's licensed clinicians can evaluate an individual's eligibility. Never stop or change any medication without guidance from your own healthcare provider.
Why screening and monitoring matter — and their limits
Facilities commonly require an EKG, blood work, and a medication review before accepting someone, and describe continuous cardiac monitoring during and after dosing. These steps are intended to identify and respond to known risks. They reduce some risks but cannot eliminate them. Ask each facility exactly what monitoring it provides, who is on site overnight, and how it handles emergencies and hospital transfers.
Cost and insurance
Programs are commonly self-paid. U.S. health insurance generally does not cover ibogaine programs abroad. Pricing structures vary, so ask each facility for a written list of what is and isn't included, along with its refund policy.
Why aftercare matters
The weeks after returning home can be an important period. Many people choose to arrange follow-up with independent licensed professionals, peer support, or other resources before they travel. IBO CLEAR can help schedule appointments with independent providers, but does not provide aftercare itself.
References
- Drug Scheduling(opens in a new tab) — U.S. Drug Enforcement Administration (DEA)
- National Institute on Drug Abuse(opens in a new tab) — NIDA
- Alper KR, Stajić M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine.(opens in a new tab) — Journal of Forensic Sciences, 2012
- Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation.(opens in a new tab) — Molecules, 2015
- Köck P, et al. A systematic literature review of clinical trials and therapeutic applications of ibogaine.(opens in a new tab) — Journal of Substance Abuse Treatment, 2022
- Knuijver T, et al. Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study.(opens in a new tab) — Addiction, 2022
- Clinical Guidelines for Ibogaine-Assisted Detoxification(opens in a new tab) — Global Ibogaine Therapy Alliance (GITA)
Titles are the authors' own; their inclusion does not suggest ibogaine treats any condition.